Chemomab Clears FDA Hurdle for PSC Drug, Eyes Single Phase 3 Trial Path
Chemomab Therapeutics achieved FDA End-of-Phase 2 approval for nebokitug in PSC treatment, establishing streamlined regulatory pathway with promising Phase 2 data.
CMMBmonoclonal antibodyPhase 3 trial